The largest cardiovascular companies had plenty of news to crow about in the latter part of February and early March as they jockeyed for position in various key sectors of the cardiovascular device market. Boston Scientific (Natick, Massachusetts) made the biggest news, reporting on March 4 that it had received its much-anticipated FDA approval to market the Taxus Express2 paclitaxel-eluting coronary stent system.